US Edition
Published • loading... • Updated
In 2036, Investors Will Regret Not Loading Up on This Multibagger in the Making
Summary by The Motley Fool
1 Articles
1 Articles
In 2036, Investors Will Regret Not Loading Up on This Multibagger in the Making
Key PointsRegeneron's shares are positioned to rise, thanks to the performance of its pipeline.Its top-selling drug, Dupixent, has already been approved for nine indications.One of Regeneron's most promising candidates is a diabetes and weight loss drug in the GLP-1 agonist family.10 stocks we like better than Regeneron Pharmaceuticals › A multibagger stock is one that has doubled your money or more. Peter Lynch, the highly respected investment …
·Alexandria, United States
Read Full ArticleCoverage Details
Total News Sources1
Leaning Left1Leaning Right0Center0Last UpdatedBias Distribution100% Left
Bias Distribution
- 100% of the sources lean Left
100% Left
L 100%
Factuality
To view factuality data please Upgrade to Premium
